Should I buy or sell RAPT Therapeutics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last twelve months. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RAPT shares. View RAPT analyst ratings or view top-rated stocks .

What is RAPT Therapeutics' stock price target for 2024?

12 analysts have issued 12-month price objectives for RAPT Therapeutics' stock. Their RAPT share price targets range from $10.00 to $41.00. On average, they expect the company's stock price to reach $25.67 in the next year. This suggests a possible upside of 229.1% from the stock's current price. View analysts price targets for RAPT or view top-rated stocks among Wall Street analysts .

How have RAPT shares performed in 2024?

RAPT Therapeutics' stock was trading at $24.85 at the beginning of the year. Since then, RAPT stock has decreased by 68.6% and is now trading at $7.80. View the best growth stocks for 2024 here .

When is RAPT Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our RAPT earnings forecast .

How were RAPT Therapeutics' earnings last quarter?

RAPT Therapeutics, Inc. (NASDAQ:RAPT) released its earnings results on Thursday, March, 7th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.05.

What ETFs hold RAPT Therapeutics' stock?

ETFs with the largest weight of RAPT Therapeutics (NASDAQ:RAPT) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) . Loncar China Biopharma ETF (CHNA) .

What is Brian Wong's approval rating as RAPT Therapeutics' CEO?

8 employees have rated RAPT Therapeutics Chief Executive Officer Brian Wong on Glassdoor.com . Brian Wong has an approval rating of 100% among the company's employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of RAPT Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include NVIDIA (NVDA) , Boeing (BA) , Slack Technologies (WORK) , Overstock.com (OSTK) , Salesforce (CRM) , Enphase Energy (ENPH) , Inovio Pharmaceuticals (INO) , Livongo Health (LVGO) , Mastercard (MA) and QUALCOMM (QCOM) .

When did RAPT Therapeutics IPO?

RAPT Therapeutics (RAPT) raised $39 million in an initial public offering on Thursday, October 31st 2019. The company issued 3,000,000 shares at a price of $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank served as the underwriters for the IPO.

Who are RAPT Therapeutics' major shareholders?

RAPT Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.15%) and Denali Advisors LLC (0.09%). Insiders that own company stock include Dirk G Brockstedt, Dirk G Brockstedt , Gino Dellomo, Group Ii Lp Column, Phuong Y Phillips, Rodney Kb Young, Wendye Robbins and William Ho . View institutional ownership trends .

How do I buy shares of RAPT Therapeutics?

Shares of RAPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Most-Downgraded StocksMost-Downgraded

NASDAQ:RAPT

RAPT Therapeutics (RAPT) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free RAPT Stock Alerts

$7.95

+0.02 (+0.25%)

(As of 04/19/2024 ET)

Compare

Today's Range: $7.62
▼
$7.96
50-Day Range: $6.87
▼
$26.45
52-Week Range: $6.86
▼
$27.35

Volume: 791,283 shs
Average Volume: 1.19 million shs
Market Capitalization: $276.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.67

Get RAPT Therapeutics alerts:

RAPT Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 229.1% Upside
$25.67 Price Target
Short Interest: Healthy
8.56% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.81
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.19) to ($2.40) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.30 out of 5 stars

Medical Sector

128th out of 918 stocks

Pharmaceutical Preparations Industry

42nd out of 417 stocks

4.3

Analyst's Opinion

Consensus Rating
RAPT Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 6 hold ratings, and no sell ratings.
Amount of Analyst Coverage
RAPT Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
8.56% of the outstanding shares of RAPT Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
RAPT Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in RAPT Therapeutics has recently decreased by 9.70%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
RAPT Therapeutics does not currently pay a dividend.
Dividend Growth
RAPT Therapeutics does not have a long track record of dividend growth.

3.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
RAPT Therapeutics has received a 44.02% net impact score from Upright. Rapt Therapeutics seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Basic medical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for RAPT Therapeutics is -0.81.

1.3

News and Social Media Coverage

News Sentiment
RAPT Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
Search Interest
Only 7 people have searched for RAPT on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added RAPT Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, RAPT Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.60% of the stock of RAPT Therapeutics is held by insiders.
Percentage Held by Institutions
99.09% of the stock of RAPT Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for RAPT Therapeutics are expected to grow in the coming year, from ($3.19) to ($2.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of RAPT Therapeutics is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of RAPT Therapeutics is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
RAPT Therapeutics has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About RAPT Therapeutics Stock (NASDAQ:RAPT)

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

RAPT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RAPT Stock News Headlines

April 12, 2024 | markets.businessinsider.com

Hold Rating on RAPT Therapeutics Amid Promising Data and Regulatory Uncertainties

April 12, 2024 | americanbankingnews.com

HC Wainwright Reiterates Neutral Rating for RAPT Therapeutics (NASDAQ:RAPT)

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 11, 2024 | investing.com

RAPT reports positive phase 2 cancer trial results

April 10, 2024 | markets.businessinsider.com

Maintaining Hold Rating on RAPT Therapeutics Amidst Mixed Clinical Results and Regulatory Uncertainty

April 9, 2024 | globenewswire.com

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

April 9, 2024 | investorplace.com

3 Biotech Stocks to Dump Before They Go to Zero

March 16, 2024 | finance.yahoo.com

RAPT Apr 2024 10.000 put

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 11, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

March 11, 2024 | markets.businessinsider.com

Hold Rating on RAPT Therapeutics Amid Clinical Trial Uncertainties and Financial Concerns

March 8, 2024 | finance.yahoo.com

RAPT Oct 2024 5.000 call

March 7, 2024 | investorplace.com

RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023

March 7, 2024 | globenewswire.com

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

March 5, 2024 | globenewswire.com

RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

March 3, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

February 26, 2024 | businesswire.com

RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

February 23, 2024 | finance.yahoo.com

RAPT May 2024 17.500 put

February 22, 2024 | msn.com

UBS Downgrades RAPT Therapeutics (RAPT)

February 21, 2024 | msn.com

HC Wainwright & Co. Downgrades RAPT Therapeutics (RAPT)

February 21, 2024 | msn.com

Leerink Partners Downgrades RAPT Therapeutics (RAPT)

February 21, 2024 | realmoney.thestreet.com

Rapt Therapeutics just downgraded at Leerink, here's why

February 21, 2024 | msn.com

J.P. Morgan cuts RAPT to neutral, recommends against buying dip

February 21, 2024 | msn.com

H.C. Wainwright cuts RAPT to neutral, cites delays due to clinical hold

February 21, 2024 | markets.businessinsider.com

What's Going On With RAPT Therapeutics Stock On Wednesday?

February 21, 2024 | finance.yahoo.com

Insider Buyers Lose Additional US$63k As RAPT Therapeutics Dips To US$236m

February 21, 2024 | realmoney.thestreet.com

Rapt Therapeutics just downgraded at JPMorgan, here's why

See More Headlines

Receive RAPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RAPT
CUSIP: N/A
CIK: 1673772
Web: www.rapt.com
Phone: (650) 489-9000
Fax: N/A
Employees: 131
Year Founded: 2015

Price Target and Rating

Average Stock Price Target: $25.67
High Stock Price Target: $41.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +232.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-116,800,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -63.14%
Return on Assets: -55.48%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.41
Quick Ratio: 7.41

Sales & Book Value

Annual Sales: $1.53 million
Price / Sales: 175.82
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.27 per share
Price / Book: 1.81

Miscellaneous

Outstanding Shares: 34,800,000
Free Float: 32,503,000
Market Cap: $269.00 million
Optionable: Optionable
Beta: 0.47

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Brian Russell Wong M.D. (Age 52)
Ph.D., CEO, President & Director
Comp: $861.24k
Mr. Rodney K. B. Young (Age 61)
CFO, Principal Accounting Officer & Secretary
Comp: $616.56k
Dr. William Ho M.D. (Age 58)
Ph.D., Chief Medical Officer
Comp: $620.32k
Steve Young Ph.D.
Vice President of Technology
Dr. Dirk G. Brockstedt Ph.D. (Age 55)
Chief Scientific Officer
Comp: $490.25k
Mr. Michael Listgarten
General Counsel
Ms. Gwen R. Carscadden (Age 63)
Chief Human Resources Officer
Dr. Paul Kassner (Age 57)
Senior Vice President of Quantitative & Computational Biology
Dr. David Wustrow (Age 65)
Senior Vice President of Drug Discovery & Preclinical Development
Ms. Jennifer Nicholson
Senior Vice President of Regulatory Affairs & Quality Assurance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RAPT Stock Analysis - Frequently Asked Questions

Should I buy or sell RAPT Therapeutics stock right now?: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last twelve months. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RAPT shares.
View RAPT analyst ratings or view top-rated stocks.
What is RAPT Therapeutics' stock price target for 2024?: 12 analysts have issued 12-month price objectives for RAPT Therapeutics' stock. Their RAPT share price targets range from $10.00 to $41.00. On average, they expect the company's stock price to reach $25.67 in the next year. This suggests a possible upside of 229.1% from the stock's current price.
View analysts price targets for RAPT or view top-rated stocks among Wall Street analysts.
How have RAPT shares performed in 2024?: RAPT Therapeutics' stock was trading at $24.85 at the beginning of the year. Since then, RAPT stock has decreased by 68.6% and is now trading at $7.80.
View the best growth stocks for 2024 here.
When is RAPT Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our RAPT earnings forecast.
How were RAPT Therapeutics' earnings last quarter?: RAPT Therapeutics, Inc. (NASDAQ:RAPT) released its earnings results on Thursday, March, 7th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.05.
What ETFs hold RAPT Therapeutics' stock?: ETFs with the largest weight of RAPT Therapeutics (NASDAQ:RAPT) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA).

What is Brian Wong's approval rating as RAPT Therapeutics' CEO?: 8 employees have rated RAPT Therapeutics Chief Executive Officer Brian Wong on Glassdoor.com. Brian Wong has an approval rating of 100% among the company's employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of RAPT Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include NVIDIA (NVDA), Boeing (BA), Slack Technologies (WORK), Overstock.com (OSTK), Salesforce (CRM), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Livongo Health (LVGO), Mastercard (MA) and QUALCOMM (QCOM).
When did RAPT Therapeutics IPO?: RAPT Therapeutics (RAPT) raised $39 million in an initial public offering on Thursday, October 31st 2019. The company issued 3,000,000 shares at a price of $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank served as the underwriters for the IPO.
Who are RAPT Therapeutics' major shareholders?: RAPT Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.15%) and Denali Advisors LLC (0.09%). Insiders that own company stock include Dirk G Brockstedt, Dirk G Brockstedt, Gino Dellomo, Group Ii Lp Column, Phuong Y Phillips, Rodney Kb Young, Wendye Robbins and William Ho.
View institutional ownership trends.
How do I buy shares of RAPT Therapeutics?: Shares of RAPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RAPT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

RAPT Therapeutics (RAPT) Stock Price, News & Analysis

RAPT Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About RAPT Therapeutics Stock (NASDAQ:RAPT)

RAPT Stock Price History

RAPT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

RAPT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™